Clinical research on antiangiogenic therapy

被引：38

作者：

Kuiper, RAJ ^{[1
]}

Schellens, JHM

Blijham, GH

Beijnen, JH

Voest, EE

机构：

[1] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands

[2] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[3] Univ Utrecht Hosp, Dept Internal Med & Med Oncol, Lab Angiogenesis Res, NL-3508 GA Utrecht, Netherlands

来源：

PHARMACOLOGICAL RESEARCH | 1998年 / 37卷 / 01期

关键词：

angiogenesis; cancer; pharmacology; clinical trials; design;

D O I：

10.1006/phrs.1997.0268

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

A promising novel target for anti-cancer therapy is the tumour vasculature. Both primary tumour growth and the formation of metastasis depend on the establishment of new blood vessels from preexisting ones, a process called angiogenesis. Inhibition of angiogenesis and targeting of the tumour vasculature are highly effective in controlling tumour growth. Several natural and synthetic compounds have been developed and are currently tested in pre-clinical and clinical studies. This review intends to provide an overview of agents with antiangiogenic activity and the early clinical experience with these drugs. (C) 1998 The Italian Pharmacological Society.

引用

页码：1 / 16

页数：16

共 223 条

[1]

Alessandro R., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P184

[2] HUMAN INTERFERON-INDUCIBLE PROTEIN-10 IS A POTENT INHIBITOR OF ANGIOGENESIS IN-VIVO [J].

ANGIOLILLO, AL ;

SGADARI, C ;

TAUB, DD ;

LIAO, F ;

FARBER, JM ;

MAHESHWARI, S ;

KLEINMAN, HK ;

REAMAN, GH ;

TOSATO, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :155-162

[3]

[Anonymous], 1995, The molecular basis of cancer

[4]

ANTOINE N, 1994, CANCER RES, V54, P2073

[5]

Antoine N, 1996, AM J PATHOL, V148, P393

[6]

ASANO M, 1995, CANCER RES, V55, P5296

[7] ANGIOGENESIS INHIBITION - A REVIEW [J].

AUERBACH, W ;

AUERBACH, R .

PHARMACOLOGY & THERAPEUTICS, 1994, 63 (03) :265-311

[8] INVIVO PATTERNS OF EXPRESSION OF UROKINASE AND ITS INHIBITOR PAI-1 SUGGEST A CONCERTED ROLE IN REGULATING PHYSIOLOGICAL ANGIOGENESIS [J].

BACHARACH, E ;

ITIN, A ;

KESHET, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (22) :10686-10690

[9] RECOMBINANT TRUNCATED THROMBOSPONDIN-1 MONOMER MODULATES ENDOTHELIAL-CELL PLASMINOGEN-ACTIVATOR INHIBITOR-1 ACCUMULATION AND PROLIFERATION INVITRO [J].

BAGAVANDOSS, P ;

KAYTES, P ;

VOGELI, G ;

WELLS, PA ;

WILKS, JW .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 192 (02) :325-332

[10] DOUBLE SCREENING OF SURAMIN DERIVATIVES ON HUMAN COLON CANCER-CELLS AND ON NEURAL CELLS PROVIDES NEW THERAPEUTIC AGENTS WITH REDUCED TOXICITY [J].

BAGHDIGUIAN, S ;

NICKEL, P ;

FANTINI, J .

CANCER LETTERS, 1991, 60 (03) :213-219

← 1 2 3 4 5 6 7 8 9 10 →